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Indications for endometrial 
ablation
• Dysfunctional uterine bleeding
• Failed traditional therapies (e.g. 
medical, dilatation and curettage)
• Contraindications to traditional 
therapies
• Poor surgical skills for anesthesia, 
hysteroscopic endometrial ablation, 
hysterectomy
• To preserve the uterus
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• Genital tract malignancy (cervical, uterine, tubal, 
ovarian)
• Unresolved endometrial hyperplasia
• Women with anatomical or pathological uterine 
anomalies
• Women with history of previous classical caesarean 
section or transmural myomectomy
• Intra-uterine pregnancy
• Acute genital and/or urinary tract infection
• Women wishing to preserve their fertility
• Women expecting amenorrhoea as an outcome
• Women with an intra-uterine contraceptive device in 
place
• Failed previous endometrial ablation
Contraindications for endometrial 
ablation
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Menometrorrhagia - Endometrial 
Ablation: 1st or 2nd generation?
First generation Second generation
• Video • Video
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Menometrorrhagia - Endometrial 
Ablation: 1st or 2nd generation?
First generation Second generation
• Hysteroscopic vision 
• Energy:
– Monopolar energy
– Bipolar energy
• General or 
locoregional 
anesthesia
• Blind technique
• Several energies
• Without general 
anesthesia
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2nd generation endometrial 
ablation techniques 
• Techniques
• Comparative studies
• Results
• Complications
• Cost effectiveness
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Daniels, BMJ 2012
Techniques
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2nd generation Endometrial
Ablation 
• Thermal Balloon (TBA)
Insertion of a silicone balloon into 
the uterine cavity. 
Hot liquid circulates inside the 
balloon.
Control of  pressure and  
temperature by the computer.
Duration: 2 to 10 minutes.
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2nd generation Endometrial
Ablation 
• Thermal Balloon (TBA)
• Microwave (MEA)
•Insertion of a microwave probe into the 
uterine cavity to heat the endometrium
•Temperature is maintained at 75-80ºC
•The probe is moved from side to side to 
destroy the endometrium
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2nd generation Endometrial
Ablation 
• Thermal Balloon (TBA)
• Microwave (MEA)
• Radiofrequency electrosurgery (RFA)
•Impedance-controlled bipolar 
radiofrequency ablation
•A triangular mesh electrode is 
expanded to fill the uterine cavity
•The electrode delivers electrical 
current and destroys the endometrial 
lining
•Temperature 45°C
•Duration of the procedure: max 15 
minutes
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2nd generation Endometrial
Ablation 
• Thermal Balloon (TBA)
• Microwave (MEA)
• Radiofrequency electrosurgery (RFA)
• Hydrothermal ablation (HTA)
– Temperature: 90°C/194°F
– Duration: 10 minutes
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2nd generation Endometrial
Ablation 
• Thermal Balloon (TBA)
• Microwave (MEA)
• Radiofrequency electrosurgery (RFA)
• Hydrothermal ablation (HTA)
• Cryoablation
A slender single-use probe is inserted into the 
uterus.
From the tip of the probe subzero temperatures 
are applied                symmetrically to the 
uterine lining
Duration: 20 to 30 minutes 
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Daniels, BMJ 2012
Network of studies evaluating 2nd generation endometrial 
destruction devices for treatment of heavy menstrual bleeding
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Amenorrhea rate at 12 months
Daniels, BMJ 2012
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HTA
Glasser et al, 2009
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TBA and RFA
• Results: 23% amenorrhea
• Predictor of amenorrhea: 
• Age ≥45 years
• Uterine length <9 cm
• Endometrial thickness <4 mm
• RFA > TBA
• 5-year cumulative failure rate:16%
El Nashar et al Obstet Gynecol 2009 
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Cumulative failure rate
El Nashar et al Obstet Gynecol 2009 
Predictors of treatment 
failure
Age <45 years
Parity ≥5
Prior tubal ligation
History of dysmenorrhea
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• Retrospective cohort study after TBA for menorraghia
• Follow up: 8 years
• Amenorrhea rate: 38% and substantial decrease in 
bleeding in 37%
• Subsequent Hysterectomy: 11%
TBA
Kopeika et al, Am 
J Obstet Gynecol 
2011
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Complications
• Perforation of the uterus 
• Minor secondary haemorrhage
• Burning of the vagina, cervix and small 
bowel 
• Serious complications occurring with 
an incidence of less than 1%
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Recommendations
• In cases of suspected uterine displacement, 
clinicians should verify the correct placement using 
ultrasound before the device is activated
• As well as the use of ultrasound for all devices, the 
use of hysteroscopy prior to the insertion of the 
ablation device is recommended if the device is not a 
balloon. This enables a check to be made that 
sounding and dilation of the cervix has not caused a 
perforation or false passage
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Cost-effectiveness: MEA vs TBA
• MEA is likely to be more cost-effective than TBA at 1 year
• The mean cost of TBALL (10 years equipment life, 100 
uses annually) of reusable equipment was £181 (95% 
confidence interval [CI] £70-434) greater than MEA
• No statistically significant differences between the total 
nonhealth costs and health benefits of the two arms
• On average, MEA provided more Quality-adjusted life-
years (QALYs)
• MEA was, on average, dominant (less costly and at least 
as effective) and there was over a 90% chance that MEA 
would be considered cost-effective at a £20,000 threshold 
of cost per QALY.Kilonzo, Value Health 2010
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• Technically easier
• Success rate and complication profiles compare 
favourably with TRE
• Less complication with 2nd generation procedure for TEA
– Fluid overload
– Uterine perforation
– Cervical laceration
– Hematometra
• More side effects: nausea, vomiting, uterine cramping
• Less effective than hysterectomy in stopping bleeding but 
is not invasive 
• Hysterectomy is associated with a higher risk for pelvic 
floor repair and surgery for SUI
Conclusions
Lethaby, Cochrane Data Base 2005
Cooper et al, BJOG 2011
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Therapeutic options for Heavy Menstrual 
Bleeding
